Abstract
Lipid-lowering therapy has been reported to reduce several oxidative stress (OS) markers in hypercholesterolemia. Since OS is frequently associated with renal dysfunction, we aimed to investigate the effect of hypolipidemic drugs on oxidative stress and plasma taurine (Tau), a sulfur amino acid with a marked antioxidant effect, in chronic kidney disease (CKD). We enrolled 30 CKD randomized to receive three different hypolipidemic regimens for 12 months: simvastatin alone (40 mg/day) or ezetimibe/simvastatin combined therapy (10/20 or 10/40 mg/day). Low molecular weight (LMW) thiols including homocysteine, cysteine, cysteinylglycine, glutathione, and glutamylcysteine in their reduced and total form and oxidative stress indices as malondialdehyde (MDA) and allantoin/uric acid (All/UA) ratio were also evaluated. Tau concentration significantly increased throughout the therapy. The rise of taurine was more striking for the group with the concomitant administration of ezetimibe/simvastatin 10/40 mg/day (+31.6% after 1 year of therapy). A significant decrease of both MDA and All/UA ratio was observed during therapy for all patients (−19% for both MDA and All/UA ratio) with a more pronounced effect in patients treated with ezetimibe/simvastatin 10/40 mg/day (−26% for MDA and −28% for All/UA ratio). Besides, an increase of thiols reduced forms was found (+20.7% of LMW thiols redox status) with a greater effect in subjects treated with ezetimibe/simvastatin 10/40 mg/day (+24.7%). Moreover, we demonstrated that oxidative stress improvement during therapy was correlated with increased taurine levels. We hypothesize that taurine may be responsible for the oxidative stress improvement observed during lipid-lowering treatment through the reduction of superoxide anion production at the respiratory chain activity level.
Similar content being viewed by others
References
Agarwal R (2004) Chronic kidney disease is associated with oxidative stress independent of hypertension. Clin Nephrol 61:377–383
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278
Cachofeiro V, Goicochea M, de Vinuesa SG, Oubiña P, Lahera V, Luño J et al (2008) Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 111:S4–S9
Carru C, Deiana L, Sotgia S, Pes GM, Zinellu A et al (2004) Plasma thiols redox status by laser-induced fluorescence capillary electrophoresis. Electrophoresis 25:882–889
Choi MJ, Kim JH, Chang KJ (2006) The effect of dietary taurine supplementation on plasma and liver lipid concentrations and free amino acid concentrations in rats fed a high-cholesterol diet. Adv Exp Med Biol 583:235–242
Conard S, Bays H, Leiter LA, Bird S, Lin J, Hanson ME, Shah A, Tershakovec AM et al (2010) Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab 12:210–218
Dembowski E, Davidson MH (2009) Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 16:183–188
Diepeveen SH, Verhoeven GH, van der Palen J, Dikkeschei BL, van Tits LJ, Kolsters G, Offerman JJ, Bilo HJ, Stalenhoef AF et al (2004) Oxidative stress in patients with end-stage renal disease prior to the start of renal replacement therapy. Nephron Clin Pract 98:c3–c7
Dierkes J, Westphal S, Luley C et al (2004) The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin Drug Saf 3:101–111
Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, Siamopoulos KC, Tsakiris D et al (2006) Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 48:752–760
Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O’Neill KA, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA et al (2005) The target of ezetimibe is Niemann–Pick c1-like 1 (npc1l1). Proc Natl Acad Sci USA 102:8132–8137
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1370
Hansen SH, Andersen ML, Birkedal H, Cornett C, Wibrand F et al (2006) The important role of taurine in oxidative metabolism. Adv Exp Med Biol 583:129–135
Huxtable RJ (1992) Physiological actions of taurine. Physiol Rev 72:101–163
Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM, Shyr Y, Himmelfarb J et al (2002) Plasma F-isoprostane levels are elevated in chronic hemodialysis patients. Clinl Nephrol 58:190–197
Jong CJ, Azuma J, Schaffer S (2011) Mechanism underlying the antioxidant activity of taurine: prevention of mitochondrial oxidant production. Amino Acids. doi:10.1007/s00726-011-0962-7
Kater AL, Batista MC, Ferreira SR (2010) Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects. Diabetol Metab Syndr 7:34–37
Kostapanos MS, Milionis HJ, Elisaf MS (2008) An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther 13:157–174
Kostapanos MS, Spyrou AT, Tellis CC, Gazi IF, Tselepis AD, Elisaf M, Liberopoulos EN et al (2011) Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress. Lipids 46:341–348
Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ et al (2003) Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 63:1121–1129
Milionis HJ, Papakostas J, Kakafika A, Chasiotis G, Seferiadis K, Elisaf MS et al (2003) Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol 43:825–830
Murakami S, Sakurai T, Tomoike H, Sakono M, Nasu T, Fukuda N et al (2010) Prevention of hypercholesterolemia and atherosclerosis in the hyperlipidemia- and atherosclerosis-prone Japanese (LAP) quail by taurine supplementation. Amino Acids 38:271–278
Ong HT (2005) The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. QJM 98:599–614
Puchades Montesa MJ, González Rico MA, Solís Salguero MA, Torregrosa Maicas I, Tormos Muñoz MC, Saez Tormo G, Juan Garcia I, Miguel Carrasco A et al (2009) Study of oxidative stress in advanced kidney disease. Nefrologia 29:464–473
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW et al (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154–2169
Schaffer SW, Azuma J, Mozaffari M (2009) Role of antioxidant activity of taurine in diabetes. Can J Physiol Pharmacol 87:91–99
Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J et al (2003) ASCOT investigators, prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149–1158
Stein EA, Ballantyne CM, Windler E, Sirnes PA, Sussekov A, Yigit Z, Seper C, Gimpelewicz CR (2008) Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 101:490–496
Suliman ME, Bárány P, Divino Filho JC, Qureshi AR, Stenvinkel P, Heimbürger O, Anderstam B, Lindholm B, Bergström J et al (2002) Influence of nutritional status on plasma and erythrocyte sulphur amino acids, sulph-hydryls, and inorganic sulphate in end-stage renal disease. Nephrol Dial Transpl 17:1050–1056
Suliman ME, Stenvinkel P, Bárány P, Heimbürger O, Anderstam B, Lindholm B (2003) Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus. Am J Kidney Dis 41:S89–S95
Vaziri ND (2006) Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290:F262–F272
Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillère-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drüeke T, Descamps-Latscha B et al (1998) Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161:2524–2532
Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C (2006) The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 47:42–50
Yokogoshi H, Oda H (2002) Dietary taurine enhances cholesterol degradation and reduces serum and liver cholesterol concentrations in rats fed a high-cholesterol diet. Amino Acids 23:433–439
Zinellu A, Carru C, Galistu F, Usai MF, Pes GM, Baggio G, Federici G, Deiana L (2003) N-methyl-d-glucamine improves the laser-induced fluorescence capillary electrophoresis performance in the total plasma thiols measurement. Electrophoresis 24:2796–2804
Zinellu A, Sotgia S, Scanu B, Chessa R, Gaspa L, Franconi F, Deiana L, Carru C (2009) Taurine determination by capillary electrophoresis with laser-induced fluorescence detection: from clinical field to quality food applications. Amino Acids 36:35–41
Zinellu A, Loriga G, Scanu B, Pisanu E, Sanna M, Deiana L, Satta AE, Carru C (2010) Increased low-density lipoprotein S-homocysteinylation in chronic kidney disease. Am J Nephrol 32:242–248
Zinellu A, Sotgia S, Deiana L, Carru C (2011a) Field-amplified online sample stacking capillary electrophoresis UV detection for plasma malondialdehyde measurement. Electrophoresis 32:1893–1897
Zinellu A, Sotgia S, Deiana L, Carru C (2011b) Field-amplified sample injection combined with pressure-assisted capillary electrophoresis UV detection for the simultaneous analysis of allantoin, uric acid, and malondialdehyde in human plasma. Anal Bioanal Chem 399:2855–2861
Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A, Remuzzi G (2010) Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. Am J Physiol Renal Physiol 299:F1203–F1211
Acknowledgments
This study was supported by the “Fondazione Banco di Sardegna, Sassari, Italy” and by the “Ministero dell’Università e della Ricerca” Italy. Angelo Zinellu was supported by Regione Autonoma della Sardegna “Ricerca cofinanziata PROGRAMMA OPERATIVO FSE SARDEGNA 2007-2013–L.R.7/2007–Promozione della ricerca scientifica e dell’innovazione tecnologica in Sardegna”. The manuscript language revision by Mrs Maria Antonietta Meloni is greatly appreciated.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Zinellu, A., Sotgia, S., Loriga, G. et al. Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy. Amino Acids 43, 1499–1507 (2012). https://doi.org/10.1007/s00726-012-1223-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-012-1223-0